Bupa fined $35m for ‘misleading or deceptive conduct' impacting 4k Aussies
Private health insurer Bupa has been fined $35m after conceding it engaged in misleading or deceptive conduct to talk more than 4000 Australians out of claiming hospital treatments.
The Australian Competition and Consumer Commission said in a statement on Monday that Bupa admitted to the breaches after telling customers they were not entitled to private health insurance benefits for their claims, even though they were entitled to make a claim.
This left some customers thousands of dollars out of pocket for medical treatments they had to pay for when Bupa should have paid at least part of the bill.
The ACCC said some policyholders also upgraded to more expensive policies to ensure they were covered.
ACCC chair Gina Cass-Gottlieb said Bupa's conduct affected thousands of members over more than five years and caused harm to consumers, some of whom delayed, cancelled or went without treatment for which they were, at least partially, covered under their health insurance policies.
'Consumers purchase private health insurance to provide peace of mind, certainty of coverage and the ability to choose where and when to undertake their procedures,' Ms Cass-Gottlieb said.
'Bupa's conduct denied certain members benefits to which they were entitled to under their private health insurance policies.'
Bupa APAC chief executive Nick Stone said he was deeply sorry for failing to get things right because customers were saddened by the impacts this has had on them or their families.
'Our priority has been to communicate and compensate our affected health insurance
customers and providers, along with putting in place measures to help ensure this does not
happen again,' Mr Stone said.
Bupa has admitted over a five-year period between May 2018 and August 2023 that it misrepresented members over two separate insurance types – 'mixed cover claims' and 'uncategorised items'.
A mixed cover claim includes both treatment that is covered in part by a customer's policy and another part covered by the customer itself.
According to Bupa, the private health insurer pays out more than $20m in claims a year as well as six million in-hospital and medical claims, with the mixed coverage claims representing less than 0.02 per cent of assessed customers over the five-year period.
Similarly, Bupa says about 0.004 per cent of claims fall under uncategorised items, which include treatments that were not assigned to a standard clinical category in Bupa's claims assessment systems.
The ACCC says Bupa's conduct occurred because Bupa staff did not have consistent and clear instructions and training for assessing mixed coverage claims, and its systems were programmed to incorrectly reject mixed coverage and uncategorised item claims.
'Private health insurance is complex, and consumers should be able to trust their health insurer to assess and pay health insurance claims accurately,' Ms Cass-Gottlieb said.
'Bupa's conduct is very serious and falls well short of what is expected of one of the largest health insurers in Australia. Bupa should have invested in the necessary systems, processes and training to prevent this from happening, and address it promptly when it occurred.'
The ACCC and Bupa will jointly ask the court to order Bupa to pay a penalty of $35m among other orders. It is a matter for the court to determine whether the penalty and other orders are appropriate.
Bupa started compensating affected members, medical providers and hospitals before the start of this legal action and has paid $14.3m for more than 4100 affected claims.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
27 minutes ago
- News.com.au
Update as alleged anti-Semitic nurses Ahmad Rashad Nadir, and Sarah Abu Lebdeh given NDIS bans
Two nurses charged with threatening to kill Israeli patients in a viral video have been banned from working with NDIS patients. Ahmad Rashad Nadir, and fellow nurse Sarah Abu Lebdeh, both aged 27, made international headlines in February after a video of the pair allegedly bragging about killing Israeli patients at Bankstown Hospital, in Sydney's west, went viral. The pair, who have both been stood down from their jobs by NSW Health, have also been hit with a two-year ban from working with NDIS participants. The order came into effect in May, a listing by the NDIS Quality and Safeguards Commission read. It prevents the nurses from working with any NDIS participants or engaging in any work for or on behalf of any NDIS provider, in any Australian state or territory. Ms Abu Lebdeh is charged with threatening violence to a group, using a carriage service to threaten to kill and using a carriage service to menace, harass or offend. Mr Nadir has been charged with using a carriage service to menace, harass or offend and possessing a prohibited drug. The pair remain on bail, and have not yet entered any pleas. However, Mr Nadir's lawyer Zemarai Khatiz told reporters outside the Downing Centre Local Court in March that he would 'intend to argue for the video to be excluded from court'. Mr Khatiz alleges the video was captured 'without the consent and knowledge' of his client. 'We will be challenging the admissibility of the video recording because it was a private conversation which was recorded by the person overseas without my client's consent and without his knowledge,' Mr Khatiz told NewsWire. 'That video recording was made secretly overseas and was unlawfully obtained.' Mr Khatiz also confirmed his client intends to plead not guilty. In the two-and-a-half minute video, recorded by Israeli influencer Max Veifer, the nurses allegedly threaten to kill Israelis who came to the hospital. Mr Veifer often uses Chatruletka and Omegle, online platforms that pair users in random video chats, to expose instances of anti-Semitism and also to learn English. 'Ahh,' Mr Nadir says in the clip. 'I'm gonna be really honest with you, you've actually got really, really beautiful eyes. 'But I'm so upset that you're Israeli … eventually you're gonna get killed and you're gonna go to Jahannam (hell). But those pretty eyes, they should stay in this world for longer.' The exchange quickly gets heated as Mr Veifer explains he served in the IDF (Israeli Defence Force). A woman's voice can then be heard off camera saying: 'you killed innocent people'. The woman's voice continues: 'So you kill innocent people to protect your country? What kind of soul do you have? You have no soul.' Mr Veifer then asked the pair: 'How are you doctors?' Abu Lebdeh then allegedly told Mr Veifer she wanted him to 'remember my face so you can understand that you will die the most disgusting death'. Mr Veifer then begins to ask 'Let's say an Israeli, God forbid …' 'I won't treat them, I'll kill them,' Ms Abu Lebdeh says. 'Not God forbid, I hope to God.' 'You'll kill them?' Mr Veifer is heard asking. Mr Nadir then said: 'OK you have no idea how many Israeli haram dogs came to this hospital and (makes throat slitting motion) I send them to Jahannam.' 'For real? If just Jewish people comes (sic) there …' Mr Veifer begins before the chat ends. Following the identification of Mr Nadir in February, Strike Force Pearl raided his home and seized a number of items. The pair will return to court at the end of the month.

Daily Telegraph
31 minutes ago
- Daily Telegraph
LTR Pharma completes ED study milestone
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. LTR Pharma & co-development partner Aptar Pharma complete extractables study on SPONTAN All identified compounds below ICH safety thresholds for nasal spray-mist erectile dysfunction treatment Leachables study initiated to support FDA regulatory submission under real-world storage conditions Special Report: LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program. LTR Pharma (ASX:LTP) said the extractables study, conducted under the supervision of co-development partner Aptar Pharma, evaluated the bottle and pump components of SPONTAN's container closure system. The study confirmed that all detected compounds were below ICH safety thresholds – the internationally recognised standards adopted by the US Food and Drug Administration (FDA) and regulatory authorities worldwide for pharmaceutical impurities. LTR Pharma said the identified compounds would be monitored in the ongoing leachables study. FDA requires extractables and leachables (E&L) studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy. For nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure. Leachables study now underway The leachables study has started under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into SPONTAN under real-world storage conditions. LTR Pharma said SPONTAN used industry-standard bottle and pump components as used in multiple FDA-approved nasal spray products. The study will run for at least 24 months to support shelf-life requirements. Consistent with FDA practice for nasal sprays, the company can submit its application once sufficient robust data is available, with study completion continuing post-approval as standard. E&L studies form part of LTR Pharma's comprehensive regulatory strategy following its FDA pre-IND meeting, where the FDA confirmed the proposed development pathway. The company said E&L data were required for the chemistry, manufacturing and controls (CMC) section of its planned new drug application (NDA). With extractables results meeting regulatory requirements, the company progresses to the leachables phase for comprehensive regulatory submission data. Watch: LTR's new appointment Progress on SPONTAN and new US-targeted ROXUS LTR Pharma continues to progress SPONTAN through established regulatory pathways while building commercial foundations through its Australian early access programs. It is also progressing its new ED nasal spray called ROXUS, which offers a fast-track pathway to serve patients through the US personalised healthcare sector. As with SPONTAN, ROXUS is based on the common active ingredient vardenafil. It will be delivered via the 503(a)-compounding pharmacy pathway, which exempts drugs from the usual approval, labelling and manufacturing requirements. "The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,' LTR Pharma executive chairman Lee Rodne said. 'Working with Aptar Pharma provides us with their established expertise in nasal spray device development and FDA submissions. 'These studies are necessary steps in our development pathway, and we look forward to progressing through each regulatory milestone." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as LTR Pharma completes study milestone for SPONTAN ED treatment


Perth Now
43 minutes ago
- Perth Now
Chris Bowen flags greater government intervention in energy markets with Gas Market Review
Labor will consider forcing gas companies to redirect future supplies into the domestic market instead of selling to international markets, with Energy Minister Chris Bowen launching a review into Australia's gas market. The Australian Competition and Consumer Commission warned on Monday Australia's east coast gas supply outlook has further deteriorated, with risks of a shortfall beginning from the fourth quarter of 2025 and into 2026 set to increase if 'Queensland LNG producers export all uncontracted gas'. This is because southern states like NSW, Victoria, South Australia and Tasmania will need to 'continually rely on gas from Queensland as their local reserves deplete,' the ACCC's interim Gas Inquiry report, published on Monday, warned. The ACCC says tipped 'structural shortfalls' on the east coast will continue from 2028 unless new gas supplies are brought online. The government's Gas Market Review will look at how regulations can be improved to ensure affordable and adequate domestic gas supply, with Mr Bowen flagging the importance of gas as a firming power, alongside renewable energy, which will make up 82 per cent of Australia's grid. Camera Icon Energy Minister Chris Bowen wants to fortify domestic gas supply for residential and industrial cusomters as the ACCC warns of a looming shortfall in the critical power source. NewsWire / Martin Ollman Credit: News Corp Australia However, he said existing commercial contracts with international partners will be protected. Australia is one of the world's largest liquid natural gas exporters with export earnings reaching a record $92.8bn in 2023. 'One thing we won't contemplate is ripping up existing contracts, creating sovereign risk, engaging in behaviours which will see Australia (considered) as an unreliable supply. 'We won't be doing that, but what we will be looking at is sensible, forward looking, prospective means to ensure that Australians get access to their gas.' While Mr Bowen wouldn't be drawn on whether this would mean ramping up gas supplies, or creating an East Coast Gas Reserve, he said it was a 'reasonable request' to ensure 'Australian users get access to Australian gas'. The review will also look at consolidating the Australian Domestic Gas Security Mechanism, Gas Market Code and Heads of Agreement with major east coast gas exporters to 'holistically' ensure policy can support the 'efficient supply of gas to industrial users, domestic users, and to the energy system'. Separately, Mr Bowen also commented on Adelaide's bid to host climate conference Cop31 in 2026, with negotiations at a standstill due as Turkey also pitches for the rights. The McMahon MP said while the bidding issue 'has not yet been resolved,' Australia had the support of the Western Europe Group. He also declined to give an estimated cost for the event, but said there would be 'revenue opportunities' through sponsorship and attendance fees. 'This is a remarkable opportunity for Australia. It's the world's largest trades fair,' he said. 'It gives us an opportunity to talk to the world about Australia's capacity to help them decarbonise. 'It's a remarkable opportunity for the Pacific (to) put their issues on the table. If and when we're successful, of course, we'll have more to say about costs.'